The legal scrutiny follows a series of regulatory setbacks that began earlier this year. On June 2, 2026, the FDA issued a warning letter detailing significant violations of Current Good Manufacturing Practice regulations, specifically noting the company’s failure to investigate unexplained batch discrepancies. Shares dropped 7 percent immediately following that disclosure. The situation worsened on August 5, 2026, when Medline executives confirmed during the company's second-quarter earnings call that remediation efforts required to address these FDA violations resulted in substantial earnings losses.

Investors who held shares during these periods are now being evaluated for potential participation in a class-action lawsuit. Bleichmar Fonti & Auld LLP, a firm known for high-profile securities litigation, is managing the investigation on a contingency fee basis. The firm is currently reviewing whether Medline provided accurate disclosures to the market concerning the severity of its supply-chain and manufacturing deficiencies.